NCT01232556

A Study Of Inotuzumab Ozogamicin Plus Rituximab For Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma Patients Who Are Not Candidates For Intensive High-Dose Chemotherapy

Nowotwór
NHL
Chorzy
oporny/nawrotowy
Faza badania
III
Sponsor badania
Pfizer
Termin
-
Dane kontaktowe
Warszawa